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Gene expression proﬁling has been used previously with spinal cord homogenates and laser capture microdissected motor
neurons to determine the mechanisms involved in neurodegeneration in amyotrophic lateral sclerosis. However, while cellular
and animal model work has focused on superoxide dismutase 1-related amyotrophic lateral sclerosis, the transcriptional proﬁle
of human mutant superoxide dismutase 1 motor neurons has remained undiscovered. The aim of this study was to apply gene
expression proﬁling to laser captured motor neurons from human superoxide dismutase 1-related amyotrophic lateral sclerosis
and neurologically normal control cases, in order to determine those pathways dysregulated in human superoxide dismutase
1-related neurodegeneration and to establish potential pathways suitable for therapeutic intervention. Identiﬁed targets were
then validated in cultured cell models using lentiviral vectors to manipulate the expression of key genes. Microarray analysis
identiﬁed 1170 differentially expressed genes in spinal cord motor neurons from superoxide dismutase 1-related amyotrophic
lateral sclerosis, compared with controls. These genes encoded for proteins in multiple functional categories, including those
involved in cell survival and cell death. Further analysis determined that multiple genes involved in the phosphatidylinositol-3
kinase signalling cascade were differentially expressed in motor neurons that survived the disease process. Functional
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sion of a single upstream target, the negative phosphatidylinositol-3 kinase regulator phosphatase and tensin homology, pro-
motes a marked pro-survival effect. Therefore, these data indicate that proteins in the phosphatidylinositol-3 kinase pathway
could represent a target for therapeutic manipulation in motor neuron degeneration.
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Introduction
Mutations in Cu/Zn superoxide dismutase (SOD1) were ﬁrst
associated with familial amyotrophic lateral sclerosis (ALS) in
1993 (Rosen et al., 1993). Following this landmark discovery,
research has focused on the pathological mechanisms of mutant
SOD1 that result in motor neuronal cell death. Oxidative stress,
mitochondrial dysfunction, excitotoxicity, protein aggregation,
endoplasmic reticulum stress, impairment of axonal transport, dys-
regulation of neuronal-glial interactions and apoptosis have all
been demonstrated to contribute to motor neuron injury in the
presence of mutant SOD1 (Shaw, 2005). Cellular and animal
models expressing mutant SOD1 have been used to investigate
strategies for therapeutic intervention, some of which have been
successful in the laboratory, but have not to date translated into
effective therapies in the clinic (Beghi et al., 2007; Aggarwal and
Cudkowicz, 2008). A greater understanding at the molecular level
of human SOD1-related ALS and how this relates to other
subtypes of familial ALS and to sporadic disease is essential for
the design of rational therapeutic approaches to neuroprotection
in ALS.
ALS is an adult onset disorder and although SOD1 is ubiqui-
tously expressed, it is the motor neurons that become selectively
injured in patients as they age. Factors contributing to this select-
ive vulnerability may include the post-mitotic nature of motor
neurons, their large size, the high level of mitochondrial activity
and their relatively low calcium buffering capacity. Thus, although
not yet deﬁned, we hypothesize that there are protective mech-
anisms initiated in response to the mutant SOD1 protein that
protect the motor neuron during the early stages of life. These
mechanisms then begin to fail during ageing, giving rise to the
neurodegenerative process after several decades. Understanding
these protective responses will allow the development of strategies
for their upregulation, with the potential to prolong the survival of
motor neuron in the face of a genetic stress.
Microarray analysis has been used previously to obtain gene
expression proﬁles from brain and spinal cord homogenates of
sporadic ALS cases in order to elucidate the genes and pathways
that are involved in the neurodegenerative process (Malaspina
et al., 2001; Ishigaki et al., 2002; Dangond et al., 2004; Offen
et al., 2009). In subsequent reports, laser capture microdissection
has been used to isolate motor neurons from the complex cell
environment of the brain and spinal cord, in order to enrich
the sample for neuronal gene expression (Jiang et al., 2005;
Wang et al., 2006). However, to date there are no reports of
the transcriptional proﬁles from human motor neurons associated
with SOD1-related ALS. The aim of this work was to generate
gene expression proﬁles of motor neurons from SOD1-related
ALS and compare them to the proﬁles of motor neurons from
neurologically normal control cases, in order to determine the
pathways implicated in human SOD1-related neurodegeneration
and to establish potential pathways suitable for therapeutic
intervention. Multiple functional categories were identiﬁed as con-
taining differentially expressed transcripts in motor neurons
expressing mutant SOD1. This report focuses on the differential
expression of cell survival and cell death genes, implicating the
phosphatidylinositol-3 kinase (PI3K) signalling cascade as an
important survival mechanism in motor neurons that remain iden-
tiﬁable in human ALS post-mortem material. This is supported by
functional studies in vitro, which demonstrate that knockdown of
the key negative regulator of the PI3K pathway, phosphatase and
tensin homologue (PTEN), supports the survival of cultured
wild-type and G93A SOD1 motor neurons.
Materials and methods
Microarray analysis
Cervical spinal cord blocks from three subjects with SOD1-related ALS
(p.E100G: n = 1, p.I113T: n = 2) and ﬁve neurologically normal control
cases (CON1–5) were obtained from the Shefﬁeld Brain Tissue Bank.
A further two control samples were obtained from NeuroResource,
Institute of Neurology, University College London (CON6–7)
(Table 1). All samples were collected following informed consent and
the work was approved by the South Yorkshire Ethics Committee.
Both p.I113T cases contained the characteristic hyaline conglomerate
inclusions associated with this SOD1 mutation (Ince et al., 1998).
Spinal cord sections were prepared, approximately 500 motor neurons
were isolated and RNA was extracted using methods described previ-
ously (Ferraiuolo et al., 2007, 2009). RNA quantity and quality was
assessed on the Nanodrop spectrophotometer and Agilent Bioanalyser,
respectively, to ensure all samples were of comparable and sufﬁ-
cient quality to proceed. RNA (20–25ng) was linearly ampliﬁed
using the Affymetrix Two Cycle cDNA synthesis protocol to produce
biotin-labelled copy RNA. Copy RNA (15mg) was fragmented for
15min and hybridized to the Human Genome U133 Plus 2.0
GeneChips, according to Affymetrix protocols. GeneChips were
washed and stained in the Fluidics System 400 before being scanned
in the GeneChip 3000 Scanner. Data analysis was performed in
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to identify differentially expressed transcripts. (Further details are avail-
able in online Supplementary material). The online Database for
Annotation, Visualization and Integrated Discovery (DAVID) (Dennis
et al., 2003; Huang da et al., 2009) and NetAffx
TM
(Affymetrix) were
used to assign Gene Ontology terms (Biological Process, Molecular
Function or Cellular Component) to each of the differentially expressed
transcripts.
Quantitative polymerase chain reaction
Total RNA was ampliﬁed using the QuantiTech Whole Transcriptome
kit (Qiagen). Quantitative polymerase chain reaction (qPCR) primers
were either designed using Euroﬁns online primer design software
(www.euroﬁnsdna.com) or were identiﬁed from previous publications
(Supplementary Table 1) (Zhou et al., 2003). QPCR of the SOD1 cases
and controls was performed using Brilliant II SYBR Green qPCR
Master Mix (Stratagene) on the Stratagene 3000, as described previ-
ously (Kirby et al., 2005). Unpaired two-tailed t-tests (Graphpad Prism
5) were used to determine if the relative differences between the
SOD1 mutant cases and controls were statistically signiﬁcant.
Small interfering RNA design and viral
production
A 19-nucleotide sequence targeting mouse PTEN (Supplementary
material) (Ning et al., 2004) was subcloned in the pLVTHM genome
vector (Addgene plasmid 12247) (Wiznerowicz and Trono, 2003)
according to the manufacturer’s protocol. This approach allowed gen-
eration of a stem-loop-stem small hairpin RNA to effectively reduce
PTEN expression levels (Brummelkamp et al., 2002). Wild-type and
mutant C124S PTEN complementary DNA were also cloned between
the BamHI/XhoI sites of a lentiviral vector genome. Self-inactivating
lentiviral vectors stocks were prepared and viral titres were estimated
using enzyme-linked immunosorbent assay (Supplementary material)
(Deglon et al., 2000).
Lentiviral transduction of NSC34 cells
Untransfected NSC34 cells and mutant G93A SOD1 stably transfected
NSC34 cells were cultured as previously described (Menzies et al.,
2002). Cells were transduced either with lentiviral vectors carrying a
PTEN knockdown small interfering RNA (multiplicity of infection = 50),
a scrambled small interfering RNA (multiplicity of infection = 50) or
with vectors expressing normal or mutant PTEN or green ﬂuorescent
protein. On post-transduction Day 5, cells were oxidatively stressed
with 10mM H2O2 for 2h and cell survival measured using a propidium
iodide assay (Supplementary material).
Lentiviral transduction of primary
motor neuron cultures
Cultures of embryonic motor neurons were prepared as described
previously (Jablonka et al., 2007) (Supplementary material). Motor
neurons were transduced with lentiviral vectors expressing the
normal or mutant PTEN or green ﬂuorescent protein or with the
PTEN small interfering RNA and scrambled small interfering RNA vec-
tors (multiplicity of infection = 10), 24h after plating. Motor neurons
for western blotting were cultured for 7 days post-transduction at
37C with 5% CO2. For survival assays, 1500 cells were plated with-
out cover slips in four-well dishes coated with polyornithine and mouse
laminin. Cells were observed under a phase-contrast microscope and
the number of initially plated cells was determined after the cells were
attached for 20h after plating. After 7 days in culture, the numbers of
surviving cells were counted.
Western blotting
Protein lysates from untransfected NSC34 cells and G93A SOD1 stably
transfected NSC34 cells were collected on Day 7 post-transduction.
For each sample, 10mg of protein was loaded on to the gel. For
western blotting of the primary motor neuron cultures, 200000 cells
were plated on 3.5cm cell culture dishes coated with polyornithine
and mouse laminin. Protein lysates were collected on Day 7
post-transduction (multiplicity of infection = 10 for lentiviral-scrambled
small interfering RNA against PTEN-green ﬂuorescent protein and
lentiviral-small interfering RNA against PTEN-green ﬂuorescent
protein). For each sample, 2mg of protein was loaded on to the gel.
Primary antibodies used were anti-mouse GAPDH antibody (1:5000;
Calbiochem), anti-rabbit PTEN (1:1000; Cell Signalling), Phospho-AKT
Ser473 (1:1000; Cell Signalling), Phospho-Bad Ser155 (1:1000; Cell
Signalling).
Results
Gene expression proﬁling of motor
neurons
Gene expression proﬁles were generated from RNA extracted from
motor neurons isolated by laser capture microdissection to ensure
a motor neuron-enriched transcriptome was sampled. RNA was
obtained from motor neurons located in the cervical spinal cord
of three SOD1-related ALS cases (mtSOD1 motor neurons)
(p.E100G: n = 1, p.I113T: n = 2) and seven neurologically normal
control cases (control motor neurons) (Table 1). Expression proﬁles
of the three mtSOD1 motor neurons gave an average of 22.1% of
genes present in the samples, compared with 28.2% of genes
present in the seven control motor neurons. Quality control par-
ameters were comparable between the two groups. Comparative
analysis in ArrayAssist identiﬁed 1170 transcripts differentially
Table 1 Details of the three SOD1-related ALS cases and
seven neurologically normal controls
Sample SOD1
status
Sex Age
(years)
PMI
(h)
Disease duration
(m)/cause of death
ALS1 p.E100G Female 40 23 41
ALS2 p.I113T Female 60 27 13
ALS3 p.I113T Female 66 50 14
CON1 Normal Female 87 14 Haemopericardium
CON2 Normal Male 53 19 Ischaemic heart disease
CON3 Normal Male 63 19 Ischaemic heart disease
CON4 Normal Male 63 20 Septic shock
CON5 Normal Female 59 5 Atypical pneumonia
CON6 Normal Male 81 19 Acute abdominal
obstruction
CON7 Normal Female 80 24 Pulmonary embolism
PMI = post-mortem interval.
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motor neurons, of which 524 were increased and 646 were
decreased in mtSOD1 motor neurons compared with controls.
(.cel ﬁles for each of the 10 GeneChips have been submitted
to the Gene Expression Omnibus Repository, Accession
GSE20589).
Functional categorization of the differentially expressed genes
revealed that the largest changes in gene expression were in
genes involved in transcription, signalling and metabolism
(Table 2). The majority of genes involved in transcription
showed decreased expression, which is in keeping with the
transcription repression induced by mutant SOD1 described in
previous reports (Kirby et al., 2005; Ferraiuolo et al., 2007).
Functional categories affected reﬂect those mechanisms known
to be involved in neurodegeneration, such as programmed cell
death, the cytoskeleton and calcium binding. In contrast, very
few RNA processing genes were differentially expressed, suggest-
ing that motor neuron cell death in SOD1-related ALS is distinct
from that proposed in TARDBP and FUS-related ALS. The com-
plete list of differentially expressed genes, classiﬁed by functional
category, is given in Supplementary Table 2. The Kyoto
Encyclopaedia of Genes and Genomes (KEGG) pathways, which
contain a signiﬁcant number of differentially expressed genes, as
identiﬁed by the Database for Annotation, Visualization and
Integrated Discovery (DAVID), are provided in Supplementary
Tables 3 and 4.
In order to focus our downstream analysis of the data, we
looked at the KEGG pathways identiﬁed as most signiﬁcantly
affected. In these highlighted pathways, it was evident that
genes involved in cell development, differentiation and survival
and in programmed cell death signalling appeared in several of
the signiﬁcant KEGG pathways. Since these genes, particularly
the PI3K/PTEN pathway, represent obvious targets for therapeutic
interventional strategies and a review of the literature provided
evidence that these genes play an important role in the CNS as
well as being dysregulated in the G93A SOD1 mouse model of
SOD1-related ALS (Warita et al., 2001; Nagano et al., 2002), we
chose to further investigate the role of these genes and their
protein interactions and validate their differential expression.
We propose that the increase in the PI3K survival pathway is
one of the neuroprotective mechanisms that determines the
late-onset of SOD1-related ALS.
Cell survival: the RHOA/PI3K/PTEN
pathway
RHOA is a member of the Rho GTPase family, intracellular
proteins that play an important role in neuronal cell survival and
cell death by transducing extracellular signals to the cytoskeleton
(Linseman and Loucks, 2008). Expression levels of RHOA are
decreased 4.25-fold in the mtSOD1 motor neurons and this was
conﬁrmed by qPCR (P = 0.0017) (Supplementary Fig. 1A). The
expression of RHOA is negatively regulated by the p110-delta
catalytic subunit (p110/PIK3CD) of phosphatidylinositol-3
kinase (PI3K) (Papakonstanti et al., 2007), which is highly
expressed in the nervous system, including in spinal cord motor
neuron (Eickholt et al., 2007). This subunit is increased (+3.95)
in mtSOD1 motor neurons and this was conﬁrmed by qPCR
(P = 0.0005) (Supplementary Fig. 1B). PI3K is a heterodimeric
enzyme that phosphorylates phosphatidylinositol-4,5-P2
(PI[4,5]P2) to phosphatidylinositol-3,4,5-P3 (PI[3,4,5]P3)
(Fig. 1A). PI[3,4,5]P3 then recruits protein kinase B (AKT) to the
membrane where AKT is activated by phosphorylation (see
below). The PIK3CD subunit also negatively regulates PTEN
(Papakonstanti et al., 2007), which shows decreased expression
in mtSOD1 motor neurons (2.07). This differential expression has
been conﬁrmed by qPCR (P = 0.0017) (Supplementary Fig. 1C).
PTEN (phosphatase and tensin homologue) is a dual phosphatase,
which negatively regulates the PI3K-AKT pathway by catalysing
the conversion of PI[3,4,5]P3 to PI[4,5]P2. PI[4,5]P2 can then be
catalysed to PI[4]P, by the action of inositol polyphosphate
5-phosphatases (IPP) and synaptojanin2, which is a ubiquitiously
expressed inositol polyphosphate 5-phosphatase. Synaptojanin2 is
decreased (3.50) in mtSOD1 motor neurons. PI[4,5]P2 can
also be converted by phospholipase C to inositol 1,4,5 triphos-
phate and diacylglycerol (Fig. 1B). Diacylglycerol activates protein
kinase C epsilon (see below) (Basu and Sivaprasad, 2007), while
inositol 1,4,5 triphosphate causes cytosolic Ca
2+ inﬂux. Thus,
the decrease in PTEN favours the PI3K pathway and activation of
AKT.
Table 2 Functional classiﬁcation of differentially expressed
transcripts in the presence of the mutant SOD1
Functional category Number
of genes
Genes
increased
Genes
decreased
Transcription 185 65 120
Signalling 139 73 66
Metabolism 103 44 59
Transport 96 47 49
Modiﬁcation 63 26 37
Nucleic acid binding 52 27 25
Cell development 48 22 26
Response 44 24 20
Cell adhesion 39 17 22
Programmed cell death 34 14 20
Cytoskeleton 33 19 14
Cell cycle 28 12 16
Translation 24 9 15
Reproduction 19 7 12
Oxidoreductase/
electron transport
19 10 9
Calcium binding 16 9 7
Protein binding 13 7 6
Development—nervous
system
12 4 8
Cell differentiation/
proliferation
12 6 6
Extracellular 7 3 4
RNA processing 4 4 0
Lipid binding 2 1 1
Miscellaneous 115 51 64
Unknown 63 24 39
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AKT3 (also known as protein kinase B gamma) is primarily ex-
pressed in the brain and has been shown to be essential for
normal brain development (Easton et al., 2005; Tschopp et al.,
2005). Once activated by phosphorylation at Thr
308 and Ser
473 by
phosphatidylinositol-3 kinase 1 and 2 (PDK1 and PDK2), respect-
ively, AKT enzymes regulate cell survival, cell cycle and prolifer-
ation and glycogen and protein metabolism (Blume-Jensen and
Hunter, 2001). AKT has been shown to inhibit the action of
B cell lymphoma 2 (Bcl2)-antagonist of death through phosphor-
ylation (Frebel and Wiese, 2006). In mtSOD1 motor neurons,
AKT3 expression is increased (+3.24) and this has been conﬁrmed
by qPCR (P = 0.02) (Supplementary Fig. 1D), and while PDK1 and
PDK2 are not differentially expressed, CD9, encoding a tetraspa-
nin that has been shown to enhance the phosphorylation of AKT
(Kotha et al., 2009), is increased (+2.83). In contrast, the level of
Bcl2-antagonist of death gene expression is decreased (2.59)
(Fig. 1C).
AKT phosphorylation has been shown to be increased by
overexpression ofprotein kinaseC epsilon. AKT can also beindirectly
regulated through protein kinase C epsilon causing an increase of
beta-1-integrin at the cell surface which subsequently triggers
the PI3K pathway (Basu and Sivaprasad, 2007) (Fig. 1C).
In mtSOD1 motor neurons, expression of protein kinase C epsilon
is increased (+5.22), as conﬁrmed by qPCR (P = 0.004)
(Supplementary Fig. 1E) as is beta-1-integrin (+2.76). Protein
kinase C epsilon also mediates anti-apoptotic signalling by altering
the expression of the BCL2 family of proteins (Basu and Sivaprasad,
2007) and this is demonstrated in the mtSOD1 motor neurons with
increased expression of the anti-apoptotic BCL2 (+2.84), as con-
ﬁrmed by qPCR (P = 0.045) (Supplementary Fig. 1F) and decreased
expression of the pro-apoptotic protein Bcl2-antagonist of death
(2.59). As mentioned previously, protein kinase C epsilon requires
diacylglycerol for activation; monoacylglycerol O-transferase 1
(MOGAT1), which synthesizes diacylglycerol, is increased in
mtSOD1 motor neurons (+2.10), while the downstream enzyme
diacylglycerol O-acyltransferase (DGAT1), which synthesizes triacyl-
glycerol, is decreased (3.59). These changes are predicted to
ensure a supply of diacylglycerol for protein kinase C epsilon and
support for cell survival (Fig. 1D).
Cell death: the programmed cell death
pathway
The differentially expressed genes PIK3CD, AKT3, protein kinase
C epsilon and BCL2 provide evidence of increased expression of
RHOA
PIK3CD
PTEN
PIP2 PIP3 PI4P
SYNJ2
PLCD1
IP3 + 
Ca
2+ influx
AKT3-P
BAD
BCL2
PDK1
PDK2
AKT3
PRKCE
MAG
MOGAT
TAG
DGAT
ITGB1
A
B
D
C
Figure 1 Interacting pathways of cell survival present in the mtSOD1 motor neurons. (A) Increase in PIK3CD, which inhibits RHOA and
PTEN, (B) the connection between PIP2, phospholipase CD1 (PLCphosp), diacylglycerol (DAG) and protein kinase C epsilon (PRKCEpr).
(C) Increased protein kinase C epsilon activates AKT3 and increases BCL2 and inhibits Bcl2-antagonist of death expression (BAD) and
(D) shows how the increase in monoacylglycerol O-transferase (MOGAT) and decrease in diacylglycerol O-acyltransferase (DGAT) ensure
levels of diacylglycerol are available for protein kinase C epsilon activation. AKT3-P = phophorylated AKT3; IP3 = inositol 1,4,5 triphos-
phate; ITGB1be = beta-1-integrin; MAG = monoacylglycerol; PI4P = phosphatidylinositol-4 phosphate; PIK3CD = phosphatidylinositol-3
kinase catalytic subunit delta; PIP2 = phosphatidylinositol-4,5-bisphosphate; RHOA = ras homology gene family member A;
SYNJ2 = synaptojanin 2; TAG = triacylglycerol.
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This is supported by additional anti-apoptotic BCL2-related genes
that show increased expression including BCL2 associated athano-
gene 4 (BAG4 +2.26) and BCL11B (+2.45). The pro-apoptotic
genes that show decreased expression, in addition to
Bcl2-antagonist of death, include apoptotic peptidase activating
factor (APAF1; 2.75), BCL2 associated transcription factor 1
(BCLAF1/BTF; 2.35), death inducer obliterator 1 (DIDO1;
2.83) and deoxyribonuclease 1 (DNASE1, 2.28).
There are also multiple genes decreased in the p53 apoptotic
pathway. Although p53 (TP53) itself is not differentially expressed,
p63 (TP63), a homologue of p53 that also induces apoptosis is
decreased (2.31). Tumour necrosis factor receptor associated
factor 4 (TRAF4), activated by both p53 and p63, is decreased
(3.75), as are other p53-induced genes, leucine-rich repeats
and death domain containing gene (LRDD; 4.80); phorbo-
12-myristate-13-acetate-induced protein 1 (PMAIP1/NOXA;
4.89); TP53 inducible protein 3 (TP53I3; 3.02) and TP53 in-
ducible protein 13 (TP53I13; 2.36). APAF1 (2.75) is also a
downstream target of p53. Inhibition of p53 can occur through
the action of mouse double minute (MDM) proteins, and MDM4
is increased 2.18 in the mtSOD1 motor neurons.
In neuronal cells, members of the inhibitor of apoptosis protein
family have previously been shown to be increased to prevent
apoptosis (Frebel and Wiese, 2006). Survivin (BIRC5) interacts
with X-linked inhibitor of apoptosis protein (XIAP/BIRC4) to in-
hibit the apoptosome, while X-linked inhibitor of apoptosis protein
also directly interacts with caspase 3, 7 and 9 to inhibit apoptosis.
Contrary to the anti-apoptotic expression changes described
above, in mtSOD1 motor neurons, both survivin (BIRC5) and
X-linked inhibitor of apoptosis protein (XIAP/BIRC4) are decreased
(2.98 and 2.43, respectively), while the pro-apoptotic septin
4, which binds X-linked inhibitor of apoptosis protein, is increased
(+2.44). However, ring ﬁnger protein 34 (RNF34), which has a
similar function to X-linked inhibitor of apoptosis protein and
increases the expression of BCL2, is increased (+2.66).
In contrast to the anti-apoptotic response demonstrated above,
there is also an increase in the pro-apoptotic apoptosis
signal-regulating kinase 1/mitogen activated protein 3 kinase 5
(ASK1/MAP3K5 +2.59). ASK1 is activated by oxidative stress
and once phosphorylated, initiates c-Jun N-terminal kinase (JNK)
and p38 MAP kinase pathways (Matsuzawa and Ichijo, 2008).
Sustained activation of these pathways by ASK1 is required for
apoptosis. However, there are no apparent downstream effectors
of ASK1, such as MAP2 kinases or JNK/p38, that show differential
expression.
Effect of PTEN knockdown on survival in
a motor neuronal cell line
The key regulators of the cell survival pathway that have been
shown have altered expression in mtSOD1 motor neurons are
PTEN (negative regulator) and PIK3CD (positive regulator).
While there are several PI3K enzymes encoded in the human
genome, there is only one functional PTEN protein. We therefore
chose to investigate the speciﬁc effect of reducing the expression
of PTEN, as a logical way to upregulate the PI3K signalling
pathway.
To demonstrate the effect of reduced expression of PTEN on
motor neuron survival in functional assays, the mouse motor neur-
onal cell line, NSC34, was transduced with a lentivirus expressing a
small interfering RNA against PTEN. The vector also encodes the
green ﬂuorescent protein reporter gene downstream from a elon-
gation factor 1 alpha EF1a promoter. Cells transduced with small
interfering RNA against PTEN showed reduced protein expression
of PTEN, while the scrambled small interfering RNA had no effect
on PTEN protein levels (Supplementary Fig. 2). Western blotting
with an antibody to PTEN demonstrated that PTEN protein expres-
sion is knocked down by 450% using small interfering RNA
against PTEN (Fig. 2A and B). Following transduction with the
small interfering RNA and scrambled small interfering RNA against
PTEN for 5 days, the NSC34 cells were stressed with 10mM H2O2
for 2h. Knockdown of PTEN by small interfering RNA was demon-
strated to signiﬁcantly increase the survival of the untransfected
NSC34 cells from 41.7–70.7% and mutant G93A SOD1 express-
ing NSC34 cells from 47 to 68% in response to this oxidative
insult (P50.05) (Fig. 2C and D).
Effect of PTEN knockdown in primary
motor neurons
To investigate whether PTEN knockdown has a similar effect in
post-mitotic neurons, puriﬁed motor neuronal cultures were trans-
duced with small interfering RNA against PTEN or scrambled small
interfering RNA against PTEN. In addition, the primary motor neu-
rons were incubated with lentivector encoding either wild-type
PTEN or a p.C124S dominant PTEN mutant (C124S), which has
no phosphatase activity. Compared with untransduced cells, the
small interfering RNA against PTEN treated motor neurons showed
a reduction of 62% in PTEN protein expression, while those trans-
duced with the wild-type or mutant PTEN showed an increase of
75% (Fig. 3A). Western blotting of the PI3K downstream targets
showed an increase in phosphorylated AKT in the presence of
small interfering RNA against PTEN and also in motor neurons
incubated with the dominant mutant C124S PTEN (Fig. 3B).
There was also a concomitant increase in the phosphorylation of
Bcl2-antagonist of death in these two motor neuron preparations
(Fig. 3C), demonstrating that reduced PTEN protein expression has
a functional effect on downstream targets.
Additional experiments using primary motor neuron originating
from the human G93A SOD1 transgenic mouse, conﬁrmed the
speciﬁcity of the small interfering RNA against PTEN to knock-
down PTEN (Fig. 4A) and this correlated with an increase in sur-
vival of motor neuron in culture at Day 7 (Fig. 4B). Small
interfering RNA against PTEN-mediated PTEN downregulation
was also shown to be associated with an increase in phosphoryl-
ation of AKT (Fig. 4C) and increased phosphorylation levels of
Bcl2-antagonist of death in primary motor neurons originating
from G93A SOD1 mice (Fig. 4D). Thus, these small interfering
RNA experiments demonstrate that the increased survival seen in
cells following PTEN knockdown are mediated through increased
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against PTEN (SsiPTEN). (A) Representative western blot illustrating the knockdown of PTEN expression in the presence of the small
interfering RNA against PTEN. The control is untransfected NSC34 cells. (B) Graph showing the level of PTEN protein expression in control
and in small interfering RNA against PTEN and scrambled small interfering RNA against PTEN transduced (green ﬂuorescent protein
positive) NSC34 cells relative to GAPDH (n =4 ;* * P50.01; values represent means  SD). (C) Effect of PTEN knockdown on survival of
untransfected NSC34 cells and (D) survival of G93A SOD1 stably transfected NSC34 cells, following treatment with 10mM H2O2 for 2h
(n =4 ;* P50.05; values represent means  SD). GFP = green ﬂuorescent protein.
Figure 3 Western blotting of primary motor neuronal cultures transfected with constructs over expressing wild-type (WT) or C124S
mutant PTEN or transduced with small interfering RNA against PTEN (siPTEN) and scrambled small interfering RNA against PTEN
(SsiPTEN). Using antibodies against (A) PTEN, (B) phosphorylated AKT and (C) phosphorylated Bcl2-antagonist of death, reduced PTEN
expression (A) is shown to be associated with increased phosphorylation of AKT and Bcl2-antagonist of death (B, C). In each graph: lane
1 = wild-type PTEN; lane 2 = dominant negative mutant C124S PTEN; lane 3 = untransfected primary motor neurons; lane 4 = scrambled
small interfering RNA against PTEN; and lane 5 = small interfering RNA against PTEN (n =3 ;* P50.05; values represent means  SD).
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ation promoting inhibition of Bcl2-antagonist of death.
Discussion
The aim of this investigation was to generate gene expression
proﬁles from motor neurons of normal human and mutant
SOD1-related ALS, to determine those pathways dysregulated in
SOD1-related ALS neurodegeneration and to establish potential
pathways for therapeutic intervention. We identiﬁed 1170 differ-
entially expressed genes in mtSOD1 motor neuron, of which 524
were increased and 646 were decreased in the presence of the
mutant SOD1 protein. While multiple functional categories of
genes were altered in expression, we focused on the signiﬁcant
differential expression of numerous genes in signalling pathways
promoting cell development, differentiation and survival, with a
concomitant decrease in programmed cell death associated
genes. We propose that these particular genes reﬂect those
expressed in motor neurons that have survived the human ALS
disease process, thereby highlighting mechanisms the motor neu-
rons are using to protect against mutant SOD1-mediated neuronal
cell death and that extension of life, through invasive ventilation,
is likely to see the balance of the survival/cell death genes switch
such that these motor neurons would also degenerate. Our
hypothesis is supported by evidence from the SOD1 transgenic
Figure 4 Results of transduction of primary motor neuronal cultures originating from G93A SOD1 mice and litter mates with small
interfering RNA (siRNA) against PTEN and scrambled small interfering RNA against PTEN (ssiPTEN). Antibodies against (A) PTEN,
(C) phosphorylated AKT and (D) phosphorylated Bcl2-antagonist of death (BAD) show the concomitant decrease in expression of PTEN
and increase in phosphorylation of AKT and Bcl2-antagonist of death (n =3 ;* P50.05, **P50.01; values represent means  SD).
(B) Survival of motor neuron in transduced primary motor neuronal cultures on Day 7 (n =3 ;* P50.05, **P50.01; values represent
means  SD). MN = motor neurons; wt = wild-type.
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occurs in the majority of large spinal cord motor neurons, prior to
disease onset (Nagano et al., 2002). However, injection of an
adenoviral vector containing glial cell line-derived neurotrophic
factor signiﬁcantly preserved the number of phosphor-AKT posi-
tive motor neurons and this was associated with an increase in the
total number of motor neurons (Manabe et al., 2002).
The role of PTEN and PI3K in
neurodegeneration
The p110 subunit of PI3K negatively regulates both RHOA and
PTEN expression (Papakonstanti et al., 2007). In the mtSOD1
motor neurons, a decreased level of RHOA is predicted to result
in maintenance of the growth cone and neurite extension, as well
as continued formation of actin/myosin cross bridges, thereby
supporting axon integrity. Increased activation of RHOA in the
CNS is associated with ischaemic injury or glutamate induced exci-
totoxicity, leading to apoptosis (Semenova et al., 2007). Thus,
reduced RHOA expression in the mtSOD1 motor neuron is pre-
dicted to reﬂect cellular conditions promoting neuronal regener-
ation and survival in motor neuron isolated at the end-stage of
disease. This conclusion is supported by the strategy taken by
Gross and colleagues (2007) who used lentiviral vectors to
reduce RHOA expression and promote regeneration of motor
neuron in models of spinal cord ischaemia.
PTEN is a tumour suppressor gene implicated in both familial
and sporadic cancers. As a key regulator of the conversion of
PI[3,4,5]P3 to PI[4,5]P2, in cancer PTEN acts to protect against
the downstream pro-proliferative, anti-apoptotic AKT-dependent
pathways (Chalhoub and Baker, 2009). In contrast, in SOD1-
related ALS, induction of anti-apoptotic pathways in the motor
neuron is predicted to be neuroprotective. The decreased expres-
sion of PTEN and concomitant increase of PIK3CD, promotes gen-
eration of the signalling molecule PI[3,4,5]P3, which is in turn
essential for activation of the downstream AKT signalling
pro-survival pathways. The importance of the activation of this
pathway in the human CNS is supported by in vitro models. In
both the NSC34 motor neuronal cell line and in primary motor
neurons, reduced PTEN protein expression is associated with an
increase in survival, increased phosphorylated (and therefore acti-
vated) AKT and increased phosphorylated (and therefore inactive)
Bcl2-antagonist of death. These ﬁndings are present in untrans-
fected cells and in the presence of G93A mutant SOD1.
PI3K, AKT and protein kinase C epsilon
as neuroprotective agents
The downstream effect of increased PI3K is increased activation of
the AKT pathway. In the mtSOD1 motor neurons, AKT3 was
increased, which in combination with the increase in protein
kinase C epsilon, would lead to increased AKT3 activation and
reduced levels of the pro-apoptotic Bcl2-antagonist of death,
while protein kinase C epsilon concomitantly causes increased
BCL2 and decreased Bcl2-antagonist of death expression (Basu
and Sivaprasad, 2007). In addition, we have shown that
phosphorylated Bcl2-antagonist of death, which is inactive, is
also increased when PTEN is inhibited (and AKT is activated). It
has been shown previously that overexpression of Bcl2 in the
G93A SOD1 transgenic mouse model delayed onset and pro-
longed survival (Kostic et al., 1997) and the result was reproduced
by adeno-associated viral injection of Bcl2 into the spinal cord
(Azzouz et al., 2000). Thus, increased expression of BCL2,
induced by protein kinase C epsilon, is neuroprotective in
mtSOD1 motor neurons. In addition, AKT3 has been implicated
previously as having a neuroprotective role against
SOD1-mediated neurotoxicity (Kanekura et al., 2005).
Multiple reports have demonstrated that the neuroprotective
effects of both vascular endothelial growth factor and angiogenin
act via PI3K to induce AKT activation. Vascular endothelial growth
factor-mediated cell survival via PI3K/AKT has been shown
in vitro in the NSC34 cell line transfected with G93A SOD1
(Li et al., 2003), rat primary motor neurons transduced with
adenoviral G93A SOD1 (Lunn et al., 2009) and in vivo in G93A
SOD1 transgenic rats (Dewil et al., 2007). Similarly, in vitro and
in vivo treatment of cultured motor neurons and G93A SOD1
mice, respectively, with angiogenin increased motor neuron sur-
vival and AKT signalling (Kieran et al., 2008). In addition, PI3K/
AKT is also activated during vascular endothelial growth
factor-mediated neuroprotection following glutamate excitotoxi-
city and serum withdrawal (Tolosa et al., 2008, 2009). Finally,
activators of PI3K, including epigallocatechin gallate, have been
shown to increase cell survival in cellular models transfected with
mutant SOD1 (Koh et al., 2004, 2005) and treatment of the
G93A SOD1 mice with epigallocatechin gallate signiﬁcantly
delayed the onset of disease, and extended life span (Xu et al.,
2006). Thus, activation of the PI3K/AKT pathway by several dif-
ferent stimuli (angiogenin, vascular endothelial growth factor, epi-
gallocatechin gallate) all result in neuroprotection and support our
evidence for the role of this pathway as a mechanism that is
protecting the surviving mtSOD1 motor neurons.
Comparison with microarray studies
of human ALS
The results presented in this report provide a novel insight into the
pathways responding to the presence of mtSOD1 in human motor
neurons that survived the neurodegenerative process prior to
death. Earlier gene expression proﬁling studies used RNA extracted
from homogenates of anterior horn spinal cord (Malaspina et al.,
2001; Ishigaki et al., 2002; Dangond et al., 2004; Lederer et al.,
2007; Offen et al., 2009) and while these studies clearly demon-
strated reactive gliosis, an inﬂammatory response and apoptotic
cell death, the differential expression primarily reﬂected the
increasing number of glial cells, rather than the loss of motor
neurons. Thus, any increased gene expression in survival pathways
of the remaining motor neurons would have been diluted by the
multiple other non-neuronal cell types in the homogenates.
More recently, laser capture microdissection has been used to
isolate lumbar spinal cord motor neurons from the surrounding
CNS tissue from sporadic and control cases, to generate motor
neuron-enriched gene expression proﬁles (Jiang et al., 2005).
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between those genes differentially expressed in sporadic ALS
lumbar motor neurons and those differentially expressed in the
SOD1-related ALS cervical spinal cord motor neurons. These cate-
gories include transcription-related genes, cell surface proteins, cell
survival and cell death associated genes and neuroprotective
neurotrophic factors, such as hepatocyte growth factor
(Supplementary Tables 2 and 3) (Jiang et al., 2005).
Comparison with microarray studies of
SOD1-related models
Microarray analysis of SOD1 models of ALS, including NSC34 cell
lines transfected with mutant G93A SOD1 and G93A SOD1 trans-
genic mice have previously been reported by the authors of this
report (Kirby et al., 2005; Ferraiuolo et al., 2007). In both of these
reports, there was evidence of a decrease in transcription, with
more genes decreased in both G93A SOD1 transfected NSC34
cells, 120d G93A SOD1 transgenic mice and in mtSOD1 motor
neurons compared with controls. Although neither of the previous
reports used genome-wide microarrays, key pathways were found
to be consistently dysregulated in the presence of mtSOD1,
including cell development, differentiation and survival, metabol-
ism and transcription.
It is important to note that the cultured murine motor neuronal
cell line, NSC34, does show a different transcriptional response to
that of post-mitotic, aged human motor neuron-enriched samples
isolated from spinal cord. Analysis of expression proﬁles from the
immortalized NSC34 cell line demonstrated an unexpected de-
crease in programmed cell life genes, in response to the presence
of human mutant SOD1, as well as a decrease in genes involved in
antigen processing and presentation (Kirby et al., 2005). Such re-
sponses have not been detected in the mtSOD1 motor neurons
isolated from the CNS or the G93A SOD1 transgenic mouse
model, most likely due to the interaction with astrocytes and
other glial cells in the CNS, which play a supporting role during
the lifetime of the motor neuron. In addition, the SOD1 transgenic
mouse model expresses mutant SOD1 protein at a level 10-fold
greater that of endogenous murine SOD1, while in the human
disease, the ratio of mutant to normal SOD1 is 1:1. Such an
increased stress and the very rapid disease course in the murine
model may account for some of the differences seen in the motor
neuron responses from the mouse model and human cases.
However, as discussed above, the SOD1 transgenic mice do
show loss of PI3K and AKT immunoreactivity in the majority of
large spinal cord motor neurons, prior to disease onset (Nagano
et al., 2002).
We present here the ﬁrst report of transcriptional proﬁling of
motor neurons from SOD1-related ALS and establish a role for the
RHOA/PI3K/PTEN and AKT3/protein kinase C epsilon pathways
as a central mechanism involved in preventing neuronal cell death
in the motor neurons that have survived the disease process in
human SOD1-related ALS. While only a small number of
SOD1-related ALS cases with a range of post-mortem intervals
have been sampled, the pathways implicated have been supported
by our functional data and evidence in the published literature.
We have demonstrated that knockdown of PTEN, which increases
PI3K signalling, promotes motor neuron survival in the presence of
oxidative stress or mutant G93A SOD1, with concomitant
increases in phosphorylated AKT and Bcl2-antagonist of death.
While it is unknown if these pathways are altered as a direct
consequence of the mutant SOD1 protein’s toxic gain of function
or as a secondary defence, the data contribute further evidence of
the potential for PI3K and AKT activators and PTEN inhibitors as
therapeutic agents to slow the progression of motor neuron
degeneration. Such agents could potentially support the intrinsic
attempts of the motor neuron to survive the cell stress induced by
the presence of mutant SOD1, a response that in human subjects
is usually successful in preventing motor neuron degeneration for
several decades.
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